Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • The company received an amended sales licence from Health Canada to allow sales to provincial distributors
  • Cannara launched its three flagship brands – Tribal, Nugz and Orchid CBD
  • Total cannabis sales of $1.22 million in Q2
  • Operating costs decreased by 33% from Q2 2020 to Q2 2021
  • Cannara Biotech Inc. is a producer of cannabis and cannabis derivative products for the Quebec and Canadian markets
  • Cannara Biotech (LOVE) is unchanged, trading at C$0.15 per share at 11:30 am ET

Cannara Biotech Inc (LOVE) announced its operating and financial results for the three and six-month periods ended February 28, 2021, and February 29, 2020.

Second Quarter Highlights

  • Received amended sales licence from Health Canada to allow sales to provincial distributors
  • Successfully launched its three flagship brands – Tribal, Nugz and Orchid CBD – and completed its first retail shipment through the Société québécoise du cannabis (SQDC) on February 25, 2021, and March 4, 2021
  • Total cannabis sales of $1.22 million (net of excise tax) in Q2 2021 compared to nil in the same period of the prior year
  • Gross profit increased from $470 thousand in Q2 2020 to $2.1 million in Q2 2021
  • Operating costs decreased by 33% from Q2 2020 to Q2 2021
  • Secured 100% occupancy of the company’s Farnham Facility
  • Completed two monthly shipments totalling 399.31 kg of dried cannabis to a wholesale partner under its one-year supply agreement which commenced January 1, 2021

Highlights Subsequent to Quarter End

  • Transitioned trading activity from the Canadian Stock Exchange (CSE) to the TSX Venture (TSXV) on April 8, 2021 under stock symbol LOVE.V for increased investor awareness
  • Signed significant one-time wholesale agreements to supply approximately 1,400 kg of cannabis for a total value of $1,265,000
  • Achieved first complete month ( March 2021 ) of net revenue generation from retail and wholesale channels of $1.8 million
  • Granted an aggregate total of 110,000 stock options to certain employees at an exercise price of $0.18 per common share, subject to certain vesting conditions
  • Extended maturity date by an additional year on one of the two mortgages

“2021 has been a transformational year for our business thus far, marked by significant milestones and a strong balance sheet. From receiving our amended sales licence from Health Canada to launching our brand portfolio through the SQDC, we are making meaningful strides to capturing market share in Quebec while positioning ourselves for long-term growth and success across Canada ,” said Zohar Krivorot, President & Chief Executive Officer of Cannara Biotech Inc.

“Our listing on the TSXV was also a major milestone of our progression that will enhance our profile as a leading producer of premium-grade cannabis products, crafted with the highest-quality genetics and at a price point that Canadians deserve.”

“Cannara is tracking well against our key performance metrics, targets and overall strategic vision. Based on our positive gross profit from our wholesale revenues and one week of retail sales in Q2, I look forward to what we can accomplish in subsequent quarters with the fully realized impact of our retail, wholesale and rental revenue channels,” Nicholas Sosiak , Chief Financial Officer of Cannara Biotech Inc.

“Bolstered by the positive reception of our flagship brands and significant wholesale agreements, we are confident in our business’ ability to build sustainable, profitable growth for our shareholders.”

Results of Operations

Cannabis Operations
For the three and six-month periods ended February 28, 2021, the segment generated $1,469,451 and $2,182,419 in revenues, net of excise tax, mainly from its wholesale clients, compared to $19,599 for the same periods of the prior year, resulting in a segmented gross profit before fair value adjustments for the three and six-month periods ended February 28, 2021, of $733,021 and $756,035, representing a gross margin before fair value adjustments of 50% and 35%, respectively.

For the three and six-month periods ended February 28, 2021 , the segment incurred $1,529,968 and $559,477 in gross profit after fair value adjustments compared to a gross profit after fair value adjustments of $19,599 in the same periods of the prior year, representing a favorable increase of $1,510,369 and $539,878 , respectively.

For the three and six-month periods ended February 28, 2021 , operating expenses were $2,050,379 and $4,086,700 compared to $2,587,854 and $4,522,784 for the same periods of the prior year. The decrease in operating expenses is mainly attributable to:

  • A decrease of $860,133 and $1,117,483 in general and administrative expenses for the three and six-month periods and a decrease of $170,428 in professional fees for the six-month period; and
  • An increase of $100,493 and $650,887 in research and development; and $133,885 and $200,940 increase in sale and marketing expenses for the three and six-month periods, respectively.

As part of the company’s capital management strategy, it has leased out all currently unoccupied space in the Farnham Facility. The company leased 425,480 square feet of the total 625,000 available square feet to two tenants. For the three and six-month periods ended February 28, 2021 , the company generated lease revenues of $752,457 and $1,309,389 compared to $641,480 and $1,169,008 in the same periods of the prior year. The increase in lease operating expenses for the six-month period is attributable to expenses incurred in the first quarter of 2021 to accommodate the new tenant.

The segment net income for the three and six-month periods ended February 28, 2021 was $558,812 and $1,016,897 compared to $451,128 and $949,024 in the same periods of the prior year, resulting in an increase of $107,684 and $67,873 in segment net income.

The company has a working capital of $7,423,458 as at February 28, 2021, including cash on hand of $4,730,524. The company has been able to maintain its working capital ratio compared to the prior year due to the access to the credit facilities and wholesale revenues generated.

The company has 741,481,321 common shares and 37,391,588 stock options issued outstanding.

Cannara Biotech Inc. is a vertically integrated producer of premium-grade indoor cannabis and cannabis-derivative products for the Quebec and Canadian markets.

Cannara Biotech (LOVE) is unchanged, trading at C$0.15 per share at 11:30 am ET.

More From The Market Herald

" BioHarvest Sciences (CSE:BHSC) appoints Steven Lehrer to its advisory board

BioHarvest Sciences (BHSC) has appointed Steven Lehrer as its newest advisory board member, effective immediately.

" CloudMD (TSXV:DOC) Receives U.S. patent approval

CloudMD Software & Services Inc. (DOC) has received US patent approval for its Real Time Intervention Platform.

" NervGen Pharma (TSXV:NGEN) introduces Spinal Cord Injury Board

NervGen Pharma Corp. (NGEN) has introduced its Spinal Cord Injury (SCI) Clinical Advisory Board.
Medicenna Therapeutics Corp - CEO, Fahar Merchant

" Medicenna (TSX:MDNA) receives FDA clearance to expand MDNA11 study

Medicenna Therapeutics (MDNA) has received FDA approval to expand the Phase 1/2 ABILITY study of MDNA11 to clinical trial sites in the US.